Qiangqiang Yin
Qiqihar, 161006, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
The upregulated RNA circ_0060055 regulates the proliferation, invasion and apoptosis of pancreatic cancer cells through spongy miR-1298-5p.
Journal: Medical oncology (Northwood, London, England)
Published: October 26, 2025
pH/GSH Dual-Responsive Janus-Type Au@H-MP@DOX MR Molecular Imaging Nanomotor for Combined Photothermal/Chemotherapeutic Treatment of Pancreatic Cancer.
Journal: Molecular pharmaceutics
Published: May 21, 2025
cRGD-based MRI imaging-enhanced nanoplatform helps DOX target pancreatic cancer.
Journal: Scientific reports
Published: November 11, 2024
Dextran Sulfate-Modified and pH-Responsive Nanoprobes for Magnetic Resonance/Fluorescence Dual-Modality Imaging of Vulnerable Plaques.
Journal: Journal of biomedical materials research. Part A
Published: August 30, 2024
Fe3O4-Cy5.5-trastuzumab magnetic nanoparticles for magnetic resonance/near-infrared imaging targeting HER2 in breast cancer.
Journal: Biomedical materials (Bristol, England)
Published: January 08, 2024
Hyaluronic acid-modified mesoporous silica nanoprobes for target identification of atherosclerosis.
Journal: Biochemical and biophysical research communications
Published: December 06, 2023
A Novel pH-Responsive Iron Oxide Core-Shell Magnetic Mesoporous Silica Nanoparticle (M-MSN) System Encapsulating Doxorubicin (DOX) and Glucose Oxidase (Gox) for Pancreatic Cancer Treatment.
Journal: International journal of nanomedicine
Published: August 20, 2023
cRGD-Conjugated GdIO Nanoclusters for the Theranostics of Pancreatic Cancer through the Combination of T1-T2 Dual-Modal MRI and DTX Delivery.
Journal: Molecules (Basel, Switzerland)
Published: June 16, 2023
Functionalized europium-doped hollow mesoporous silica nanospheres as a cell imaging and drug delivery agents.
Journal: Biochemical and biophysical research communications
Published: May 30, 2023
Magnetic resonance/fluorescence dual-modality contrast agents targeting αvβ6-overexpressing tumors based on A20FMDV2 peptide as a ligand.
Journal: Biochemical and biophysical research communications
Published: March 22, 2023
Showing 1-10 of 10
Last Updated: 09/26/2026